Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapses and refractory lymphoma

Investigational New Drugs

Volumn 15, Issue 3, 1997, Pages 247-253

  Richardson, Deborah S ^a   Kelsey, Stephen M ^a   Johnson, Stephen A ^b   Tighe, Mary ^b   Cavenagh, James D ^a   Newland, Adrian C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Daunorubicin; Liposomes; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEART FUNCTION; HUMAN; LIVER TOXICITY; LYMPHOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; LIPOSOMES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 0030667453     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005879219554     Document Type: Article

References (22)

1. Tan C, Tasaka H, Yu K-P, Murphy ML, Karnofsky DA: Daunomycin, an antitumour antibiotic, in the treatment of neoplastic disease. Cancer 20: 333-353, 1967.
2. Von Hoff DD: Use of daunorubicin in patients with solid tumours. Semin Oncol 11(4) (suppl.) 3: 23-27, 1984.
3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Evonne M, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
4. Hale JP, Lewis IJ: Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child 71: 457-462, 1994.
5. Carlson RW: Reducing the cardiotoxity of the anthracyclines. Oncology (Huntingt) 6: 95-105, 1992.
6. Guaglianone P, Chan K, DelaFlor-Weiss E, hanisch R, Jeffers S, Sharma D, Muggia F: Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12: 103-110, 1994.
7. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996-1003, 1995.
8. Rahman A, Treat J, Roh J-K, Potkul LA, Alvord WG, Forst D, Woolley PV: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8: 1093-1100, 1990.
9. Forssen EA, Ross ME: DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4: 481-512, 1994.
10. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Rose ME: Lack of cardiac toxicity of liposomal encapsulated daunorubicin (DaunoXome) after long term use in AIDS-related Kaposi's sarcoma. Proc 9th NCI-EORTC symposium in new drugs in cancer therapy: (Absr.) 496, 1996.
11. Rahman A, Fumagalli A, Goodman A, Schein PS: Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 11(4) (suppl.) 3: 45-55, 1984.
12. Gray A, Morgan J: Liposomes in haematology. Blood Rev 5: 258-272, 1991.
13. Forssen EA, Coulter DM, Proffitt RT: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3255-3261, 1992.
14. Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S, Tromberg BJ: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue. Cancer Res 56: 2066-2073, 1996.
15. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242-1243, 1993.
16. Money-Kryle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC: Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 5: 367-371, 1993.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
18. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
19. Von Hoff DD, Rozencwieg M, Layard M, Slavik M, Muggia FM: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62: 200-208, 1977.
20. Jiang XR, Kelsey SM, Wu YL, Gutteridge CN, Newland AC: Restoration of DaunoXome sensitivity of multidrug-resistant cells by SDZ PSC833. Proc AACR 36: (absr.) 2043, 1995.
21. Coley HM, Twentyman PR, Workman P: Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 38: 4467-4475, 1989.
22. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg R, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259, 1992.